[go: up one dir, main page]

MX2010004389A - Formulaciones de vancomicina liposomales. - Google Patents

Formulaciones de vancomicina liposomales.

Info

Publication number
MX2010004389A
MX2010004389A MX2010004389A MX2010004389A MX2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A MX 2010004389 A MX2010004389 A MX 2010004389A
Authority
MX
Mexico
Prior art keywords
liposomal vancomycin
vancomycin formulations
liposomal
present disclosure
compositions
Prior art date
Application number
MX2010004389A
Other languages
English (en)
Inventor
Xingong Li
Walter R Perkins
Original Assignee
Transave Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transave Inc filed Critical Transave Inc
Publication of MX2010004389A publication Critical patent/MX2010004389A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere en parte a composiciones de vancomicina liposomales que tienen bajas relaciones de lípidos a fármacos y alta concentración de vancomicina. La presente descripción también se refiere en parte a métodos para formar dichas composiciones.
MX2010004389A 2007-10-23 2008-10-23 Formulaciones de vancomicina liposomales. MX2010004389A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98199007P 2007-10-23 2007-10-23
US10372508P 2008-10-08 2008-10-08
PCT/US2008/080954 WO2009055568A2 (en) 2007-10-23 2008-10-23 Liposomal vancomycin formulations

Publications (1)

Publication Number Publication Date
MX2010004389A true MX2010004389A (es) 2010-05-20

Family

ID=40563728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004389A MX2010004389A (es) 2007-10-23 2008-10-23 Formulaciones de vancomicina liposomales.

Country Status (8)

Country Link
US (2) US20090105126A1 (es)
EP (1) EP2214645A4 (es)
JP (3) JP5855829B2 (es)
CN (2) CN103860469A (es)
AU (2) AU2008316841B2 (es)
CA (1) CA2703179C (es)
MX (1) MX2010004389A (es)
WO (2) WO2009055568A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2594368T3 (es) 2005-12-08 2016-12-19 Insmed Incorporated Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2011146829A1 (en) * 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
AU2011268101B2 (en) * 2010-06-19 2014-09-25 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
JPWO2012020790A1 (ja) * 2010-08-11 2013-10-28 学校法人慶應義塾 感染症治療薬
WO2012054447A2 (en) * 2010-10-22 2012-04-26 Dr. Reddy's Laboratories, Inc. Use of storage stable viscous phospholipid depot to treat wounds
MX2013012603A (es) * 2011-04-26 2014-04-25 Cedars Sinai Medical Center Vancomicina liposomal para el tratamiento de infecciones por estafilococo aureus resistente a la meticilina (sarm).
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
JP5932993B2 (ja) * 2011-06-17 2016-06-08 バーグ エルエルシー 吸入可能な医薬組成物
ES2743039T3 (es) * 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
ES2926985T3 (es) 2014-05-15 2022-10-31 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
US20170065520A1 (en) * 2015-09-09 2017-03-09 Manli International Ltd Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer
PL3373910T3 (pl) * 2015-11-10 2023-10-09 Children's Research Institute, Children's National Medical Center Preparat echinomycyny, sposób wytwarzania i sposób stosowania
CN108601730B (zh) * 2016-01-15 2021-10-26 赛多斯制药有限责任公司 万古霉素的制剂
CN116549393A (zh) * 2017-03-02 2023-08-08 康柏辛股份有限公司 抑制生物膜形成的脂质体
NZ758839A (en) 2017-05-22 2025-08-29 Insmed Inc Glycopeptide derivative compounds and uses thereof
US20200368313A1 (en) * 2017-12-29 2020-11-26 Wayne State University Drug delivery systems for treatment of infections
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
CA3098573A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
EP3883589A4 (en) * 2018-11-21 2022-05-25 Insmed Incorporated LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF
WO2020242996A1 (en) * 2019-05-28 2020-12-03 Nevakar Inc. Vancomycin liposome compositions and methods
CN119499182B (zh) * 2024-11-28 2025-08-26 西藏农牧学院 一种黄枝瑚菌多糖脂质体及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203504A (es) * 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
JPH06345663A (ja) * 1993-06-08 1994-12-20 Sumitomo Pharmaceut Co Ltd バンコマイシン含有リポソーム製剤
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
NZ540087A (en) * 2002-10-29 2008-09-26 Transave Inc Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
CA2506749A1 (en) * 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
US20070105756A1 (en) * 2005-10-31 2007-05-10 May Thomas B Vancomycin formulations having reduced amount of histamine

Also Published As

Publication number Publication date
CN103860469A (zh) 2014-06-18
EP2214645A4 (en) 2013-09-25
JP2011500836A (ja) 2011-01-06
JP2014098032A (ja) 2014-05-29
CN101917972A (zh) 2010-12-15
AU2014202745A1 (en) 2014-06-12
JP2016130262A (ja) 2016-07-21
AU2008316841A1 (en) 2009-04-30
WO2009055568A2 (en) 2009-04-30
CA2703179C (en) 2016-06-07
US20090105126A1 (en) 2009-04-23
WO2009055571A2 (en) 2009-04-30
CA2703179A1 (en) 2009-04-30
WO2009055568A3 (en) 2009-09-24
EP2214645A2 (en) 2010-08-11
JP5855829B2 (ja) 2016-02-09
AU2014202745B2 (en) 2016-11-24
AU2008316841B2 (en) 2014-04-17
US20090104257A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
MX2010004389A (es) Formulaciones de vancomicina liposomales.
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
EP4495237A3 (en) Novel lipids and compositions for the delivery of therapeutics
WO2009099719A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
GEP20156253B (en) Lyophilized therapeutic peptibody formulations
CA2818187C (en) Bromodomain inhibitors and uses thereof
WO2009149418A3 (en) Compositions for the in vivo delivery of rnai agents
MY161991A (en) Proteasome inhibitors
MX2009003548A (es) Formulaciones que contienen lipidos.
PH12012502159A1 (en) Pharmaceutical compositions and methods of making same
PH12015501193A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MX2012001660A (es) Formulaciones que contienen linaclotida para adminstracion oral.
EP3626253A3 (en) Stable formulations of linaclotide
PH12012502406A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX2010000266A (es) Un método para disminuir los síntomas del consumo de alcohol.
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
MY161390A (en) Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
PL2320740T3 (pl) Kompozycje farmaceutyczne klewidypiny oraz sposoby ich wytwarzania z niskim stężeniem zanieczyszczeń
WO2009130616A3 (en) Improved tlr3 agonist compositions
WO2008016730A3 (en) Compositions and methods for reducing cellular fat
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.

Legal Events

Date Code Title Description
FG Grant or registration